Regulus Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

Regulus Therapeutics

21/03/2024 21:28

* Regulus Therapeutics Inc  RGLS.OQ  reported a quarterly
adjusted
loss of 40 cents​​ per share for the quarter ended in December,
identical to the same quarter last year.  The mean expectation
of four analysts for the quarter was for a loss of 39 cents per
share. Wall Street expected results to range from -41 cents
to -38 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Regulus Therapeutics Inc's reported EPS for the quarter
was a
loss of 40 cents​.
    * The company reported a quarterly loss of $8.06 million.
    * Regulus Therapeutics Inc shares had risen by 95.3% this
quarter.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 2.1%
in the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Regulus
Therapeutics Inc is $6.00 
This summary was machine generated from LSEG data March 21 at
09:27 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.39          -0.40          Missed
 Sep. 30 2023      -0.40          -0.40          Met
 Jun. 30 2023      -0.41          -0.37          Beat
 Mar. 31 2023      -0.44          -0.42          Beat